220 related articles for article (PubMed ID: 24283603)
1. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis.
Cai J; Ma H; Huang F; Zhu D; Bi J; Ke Y; Zhang T
World J Surg Oncol; 2013 Nov; 11():306. PubMed ID: 24283603
[TBL] [Abstract][Full Text] [Related]
2. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
3. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
5. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
[TBL] [Abstract][Full Text] [Related]
7. Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis.
Chen C; Sun P; Ye S; Weng HW; Dai QS
J BUON; 2014; 19(4):917-24. PubMed ID: 25536596
[TBL] [Abstract][Full Text] [Related]
8. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
10. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Barni S
Med Oncol; 2013; 30(3):650. PubMed ID: 23828442
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
Cao Y; Tan A; Gao F; Liu L; Liao C; Mo Z
Int J Colorectal Dis; 2009 Jun; 24(6):677-85. PubMed ID: 19184059
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
Cao D; Zheng Y; Xu H; Ge W; Xu X
Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
[TBL] [Abstract][Full Text] [Related]
13. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
[TBL] [Abstract][Full Text] [Related]
14. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
Hurwitz HI; Tebbutt NC; Kabbinavar F; Giantonio BJ; Guan ZZ; Mitchell L; Waterkamp D; Tabernero J
Oncologist; 2013; 18(9):1004-12. PubMed ID: 23881988
[TBL] [Abstract][Full Text] [Related]
16. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hypertension as a marker of bevacizumab efficacy.
Ryanne Wu R; Lindenberg PA; Slack R; Noone AM; Marshall JL; He AR
J Gastrointest Cancer; 2009; 40(3-4):101-8. PubMed ID: 19921473
[TBL] [Abstract][Full Text] [Related]
18. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis.
Galfrascoli E; Piva S; Cinquini M; Rossi A; La Verde N; Bramati A; Moretti A; Manazza A; Damia G; Torri V; Muserra G; Farina G; Garassino MC;
Dig Liver Dis; 2011 Apr; 43(4):286-94. PubMed ID: 21146479
[TBL] [Abstract][Full Text] [Related]
19. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Scartozzi M; Galizia E; Chiorrini S; Giampieri R; Berardi R; Pierantoni C; Cascinu S
Ann Oncol; 2009 Feb; 20(2):227-30. PubMed ID: 18842611
[TBL] [Abstract][Full Text] [Related]
20. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
